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Abstract 
Objective: Survivors of Ebola virus disease (EVD) are at risk of developing blinding intraocular inflammation—or 
uveitis—which is associated with retinal pigment epithelial (RPE) scarring and persistence of live Zaire ebolavirus 
(EBOV) within the eye. As part of a large research project aimed at defining the human RPE cell response to being 
infected with EBOV, this work focused on the microRNAs (miRNAs) associated with the infection.
Results: Using RNA-sequencing, we detected 13 highly induced and 2 highly repressed human miRNAs in human 
ARPE-19 RPE cells infected with EBOV, including hsa-miR-1307-5p, hsa-miR-29b-3p and hsa-miR-33a-5p (up-regu-
lated), and hsa-miR-3074-3p and hsa-miR-27b-5p (down-regulated). EBOV-miR-1-5p was also found in infected RPE 
cells. Through computational identification of putative miRNA targets, we predicted a broad range of regulatory activ-
ities, including effects on innate and adaptive immune responses, cellular metabolism, cell cycle progression, apopto-
sis and autophagy. The most highly-connected molecule in the miR-target network was leucine-rich repeat kinase 2, 
which is involved in neuroinflammation and lysosomal processing. Our findings should stimulate new studies on the 
impact of miRNA changes in EBOV-infected RPE cells to further understanding of intraocular viral persistence and the 
pathogenesis of uveitis in EVD survivors.
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Introduction
Survivors of Ebola virus disease (EVD) suffer long-term 
sequelae. Intraocular inflammation—termed uvei-
tis—develops in 18–34% of survivors [1, 2], and 40% of 
affected persons become blind [3]. Live Zaire ebolavirus 
(EBOV) has been isolated from intraocular fluid after 
resolution of the viremia [4], and retinal scars that indi-
cate involvement of the retinal pigment epithelium are 
associated with uveitis [3]. Zaire ebolavirus may persist 
at immune-privileged sites, such as the eye, since local 
immune responses are attenuated to avoid tissue damage. 
We previously demonstrated that human retinal pigment 
epithelial (RPE) cells mount a type I interferon (IFN) 
anti-viral response and maintain immunomodulatory 
activity when infected with EBOV, and this cell popula-
tion may be a reservoir for EBOV in the eye [5].
MicroRNAs (miRNAs) are short (18–22 nt) fragments 
of single-stranded RNA that bind the 3′ untranslated 
region of mRNA, and directly suppress or indirectly acti-
vate gene expression. Because only a small (7–8 nt) “seed 
region” requires complementarity to permit binding, 
a single miRNA may have hundreds of mRNA targets, 
and thus play a complex regulatory role in cellular activ-
ity that varies by cell type and disease state [6]. We used 
small RNA sequencing (RNA-Seq) to identify miRNA 
expression in EBOV-infected human RPE cells, and con-
ducted in silico analyses to identify biological targets of, 
and molecular interactions with, these miRNAs.
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Methods
Total RNA was sourced from our previous study [5], 
in which the human RPE cell line (ARPE-19) [7] was 
infected in triplicate with EBOV (multiplicity of infec-
tion, 5) or mock-infected for 24  h. From 1  μg of RNA 
extract, small RNA was selectively enriched through 
sequential adapter ligation to 3′ and 5′ ends of RNA frag-
ments using the TruSeq Small RNA Library Preparation 
Kit (Illumina, San Diego, CA). Single-stranded cDNA 
was synthesized by reverse transcription, and separately 
amplified with polymerase chain reaction using one of 
48 primers containing index sequences (11 cycles). Using 
the Pippin Prep DNA Size Selection System (Sage Sci-
ence, Beverley, MA), amplified cDNA constructs were 
purified from 3% agarose gel to isolate a library of small 
clone fragments. The library was sequenced on Illumina 
NextSeq 500, using NextSeq 75-cycle High Output Kits 
(Illumina), with the PhiX Control v3 library (Illumina) as 
sequencing control.
Short reads were filtered for adapters and reads of 
low quality using Cutadapt (v.1.8) [8] with error rate of 
0.2 and minimum length of 18 bp, aligned against GEN-
CODE human genome reference assembly GRCh38.
p3 using Burrows Wheeler Aligner [9], and assigned to 
miRBase (v.21) annotations using HTSeq (v.0.6.1p2) 
[10, 11]. Data were filtered for targets with a minimum 
of 10 counts in at least 50% of samples. After normaliza-
tion, differentially expressed miRNAs between EBOV- 
and mock-infected ARPE-19 cells were identified using 
the DESeq 2 statistical package (v.3.2) [12]. Reads were 
screened for complete matches to published EBOV 
miRNA sequences, allowing for 3 mismatches [13]. Raw 
data from our RNA-Seq study of the total RNA tran-
scriptome of EBOV-infected ARPE-19 cells [5] (https ://
www.ncbi.nlm.nih.gov/geo/query /acc.cgi?acc=GSE10 
0839) were processed in the same statistical pipeline used 
for human miRNAs, to identify genes that were differ-
entially regulated with adjusted p-value ≤ 0.05 and log2 
fold-change ≥ 1.
Computational predictions of the targets of differen-
tially expressed human miRNAs (defined by adjusted 
p-value < 0.001 and log2 fold-change > 1) were performed 
using public databases with different algorithms: Diana 
microT CDS (v.5.0) [14, 15], filtering with a threshold of 
0.95; TargetScan (v.7.1) [16], sorting on a total context 
score < 0.15; and miRDB (v.5.0) [17], with a target thresh-
old > 85. The human miRNAs were also input into pub-
lic online repositories of experimentally-validated data 
on molecular interactions: miRecords (release 2013) and 
miRTarBase (v.7.0) [18, 19], set to ‘strong evidence’.
Gene ontology [20] and pathway analyses were per-
formed using Cytoscape (v.3.4.0) and ClueGO (v.2.3.3) 
plugin [21, 22], to identify enriched biological processes 
and molecular functions, and Kyoto Encyclopedia of 
Genes and Genomes (KEGG) pathways [23]. Using the 
STRING Action dataset (v.9) within CluePedia plugin 
(v.1.3.3) [24, 25] and collating miRNA-gene pairs, a 
miRNA-based network was constructed from miRNA-
predicted gene target lists, miRNA-validated target gene 
lists, and the differentially expressed gene list; interac-
tions were demonstrated based on degree, to identify the 
most highly-connected genes and miRNAs. An inverse 
correlation was required between expression of an 
miRNA and its target gene in these analyses.
Results
RNA sequencing yielded 1.61–2.87 × 107 reads per 
replicate (Additional file  1). Filtering for size, 91–97% 
of trimmed sequences were mapped to the human 
genome. 814 human miRNAs were identified (Additional 
file  2), and multidimensional scaling showed separation 
between results for EBOV- and mock-infected human 
RPE cells (Additional file 3). Defining differential expres-
sion as adjusted p-value < 0.05, 28 and 61 miRNAs were 
significantly increased and decreased, respectively, in 
EBOV-infected cells. Filtering stringently for adjusted 
p-value < 0.001 and log2 fold-change > 1, 13 and 2 miR-
NAs were significantly increased and decreased (Table 1). 
EBOV-miR-1-5p, EBOV-miR-T1-3p, EBOV-miR-T1-5p 
and EBOV-miR-T3-5p/T4-5p were identified in the 
infected human RPE cells (Additional file 4).
Putative target genes in EBOV-infected human RPE 
cells were predicted from the 15 highly differentially 
Table 1 List of  miRNAs that  were differentially expressed 
between  EBOV- and  mock-infected human RPE cells 
at 24 h post-infection
miRNA log2 fold-change Adjusted p-value
hsa-miR-3074-3p − 1.52 1.24 × 10−12
hsa-miR-27b-5p − 1.06 2.63 × 10−13
hsa-miR-101-5p 1.03 3.09 × 10−8
hsa-miR-33b-5p 1.04 8.18 × 10−5
hsa-miR-190a-3p 1.06 6.30 × 10−5
hsa-miR-1305 1.10 3.92 × 10−6
hsa-miR-130a-5p 1.19 3.15 × 10−5
hsa-miR-32-5p 1.21 2.39 × 10−6
hsa-miR-365a-5p 1.24 2.39 × 10−6
hsa-miR-100-3p 1.27 1.19 × 10−13
hsa-miR-33b-3p 1.33 7.05 × 10−10
hsa-miR-4521 1.37 2.63E−13
hsa-miR-33a-5p 1.41 5.10E−04
hsa-miR-29b-3p 1.47 2.24E−08
hsa-miR-1307-5p 1.50 1.98E−10
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expressed miRNAs using algorithms: 2629 targets by 
Diana microT; 1799 targets by miRDB; and 14,315 targets 
by TargetScan (Additional file 5). Targets were also iden-
tified through interrogation of experimentally validated 
data: 44 targets by miRecords; and 9 targets by miRTar-
Base (Additional file  6). 1440 genes were differentially 
expressed between EBOV- and mock-infected ARPE-19 
cells (Additional file  7). Highly enriched gene ontology 
categories and KEGG pathways were established for the 
target genes, based on numbers represented within cat-
egories and pathways, and ranking of corrected p-values 
(Fig. 1a–c, Additional file 8). The molecular network con-
structed from miRNA-target gene interactions included 
363 highly connected molecules; most connected mole-
cule was leucine-rich repeat kinase 2 (LRRK2), and most 
connected miRNA was hsa-miR-190a (Fig.  1d, Table  2, 
Additional files 9 and 10).
Discussion
Zaire ebolavirus causes uveitis in EVD survivors [26, 27]. 
We have identified miRNAs produced in human RPE cells 
following infection with EBOV. Viruses take advantage 
of host miRNAs to adjust gene expression and create an 
environment that supports replication [28]. Human RPE 
cells make multiple molecular adjustments in response to 
infection with EBOV [5], and miR-190a is central to the 
cell response. This highly connected miRNA contributes 
to cell survival and latency in Epstein–Barr virus (EBV) 
infection, by downregulating expression of tumor pro-
tein P53 inducible nuclear protein 1 and nuclear recep-
tor subfamily 4 group A member 3, thereby preventing 
cell cycle arrest and inhibiting apoptosis [29]. The same 
mechanism may be utilized by EBOV to promote viral 
replication in infected RPE cells. One other interacting 
miRNA—miR-101—prevents cell death in the context of 
herpes simplex virus type 1 infection [30], pointing to a 
common strategy among viruses to promote survival of 
both the virus and its host cell.
Another highly connected miRNA was miR-29b3p, 
which suppresses key immunological pathways by down-
regulating nuclear factor kappa-light-chain-enhancer 
of activated B cells (NF-κB) [31]. This transcription fac-
tor plays an essential role in the anti-viral type IFN 
response. Multiple receptors—including toll-like recep-
tors and retinoic acid-inducible gene (RIG)-I—stimu-
late NF-κB, which activates transcription of IFN-β and 
IFN-stimulated genes. Zaire ebolavirus profoundly inhib-
its the type I IFN response in monocytes and other cell 
populations, through the action of viral proteins—VP24 
and VP35—and suppression of RIG-I signaling [32]. Our 
prior work has demonstrated that EBOV-infected RPE 
cells mount a type I IFN response [5]; however, EBOV 
also may suppress this pathway through activation of 
miR-29b-3p. Other viruses act similarly: the NF-κB path-
way is not activated in human RPE cells infected with 
cytomegalovirus [33]. MicroRNA-29b is also activated in 
Japanese encephalitis virus infection, particularly in per-
sons with neurological sequelae, and elevated serum lev-
els may indicate severe disease [34].
After entering the host cell, EBOV is transported via 
endolysosomal trafficking [35]. Infected cells also release 
exosomes containing EBOV VP40, which may promote 
leukocyte apoptosis [36]. Consistent with involvement 
of the endolysosomal system, the most highly connected 
molecule in the miRNA-target gene network was LRRK2. 
This protein is a key regulator of the system; a range of 
mutations in LRRK2 result in formation of large, dys-
functional lysosomes [37]. Interestingly, LRRK2 activa-
tion in microglia has been implicated in the progression 
of central nervous system inflammation, as occurs in 
Parkinson’s disease and HIV-associated neurocognitive 
disorders [38]. This suggests LRRK2 activity in EBOV-
infected RPE cells may contribute to the development of 
uveitis.
As applies to all viruses, EBOV infection involves 
hijacking translational machinery of the host cell to pro-
duce viral particles. Gene ontology enrichment analysis 
for molecular function showed strong activation of DNA-
binding and transcription pathways in EBOV-infected 
human RPE cells. Known to bind double-stranded RNA, 
multiple genes in the 2′-5′-oligoadenylate synthetase 
pathway were upregulated in our gene ontology enrich-
ment analyses, indicating a miRNA-facilitated host 
response to EBOV. Activation of kinases was prominent; 
pathways involving kinases—such as protein kinase R—
are directly involved in the response to EBOV, binding 
to double-stranded RNA, activating cellular targets and 
inhibiting the host translational machinery [39].
Virus-infected cells release exosomes contain-
ing host- and virus-derived miRNAs that modulate 
gene expression in uninfected neighbouring cells [40]. 
Human RPE cells have the capacity to secrete exosomes 
Fig. 1 a–c Graphs showing enriched gene ontology categories: a biological process, b molecular function and c KEGG pathways in human RPE 
cells 24 h post-infection with EBOV. Percentages indicate proportion of known genes represented within the grouping. d Network of interactions 
between protein-coding genes and miRNAs in EBOV-infected human RPE cells, with miRNAs indicated by yellow diamonds, molecules indicated by 
blue circles, and interactions that are promoting or inhibiting represented as blue or red lines, respectively. Size of circle or diamond is proportionate 
to the number of molecular interactions (or degrees). An enlarged version of d is presented as Additional file 8
(See figure on next page.)
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containing miRNAs [41]. Our data indicate that hsa-
miR-27b-5p and hsa-miR-3074-3p are expressed at 
reduced levels when the cells become infected with 
EBOV, which might indicate active export of the miR-
NAs into exosomes. Both miRNAs are detected in 
the aqueous humour of healthy eyes, at levels higher 
than found in plasma indicating local production [42]. 
We speculate that levels of these miRNAs might be 
increased in the ocular fluid of EBOV survivors, par-
ticularly those with uveitis and present biomarkers for 
ocular involvement. Other investigators have identified 
a panel of 8 serum miRNAs that predict pre-sympto-
matic EBOV infection, facilitating an early diagnosis of 
EVD [43].
RNA viruses do not typically encode miRNAs [28]. 
However, our analysis of EBOV-infected RPE cells 
identified EBOV-miR-1-5p, which has been described 
by several investigator teams [13, 44]. This ortholog of 
human miR-155 inhibits expression of importin-α5 and 
impacts type I IFN signaling [45]. Molecular mimicry 
of miR-155 is also seen in Kaposi sarcoma herpesvirus 
infection of B-cells, enabling the virus to drive the cell 
to a state that supports long-term latency and avoids 
apoptosis [46]. Several other EBOV-derived miRNAs 
were identified in the infected RPE cells, but with 
very low read counts suggesting negligible biological 
activity.
Conclusion
Our work provides new information about the potential 
post-transcriptional regulation of the human RPE cell 
response to infection with EBOV. Review of the biologi-
cal targets of the 15 highly-induced or repressed miRNAs 
indicates a broad range of potential regulatory activities, 
including effects on immune responses, cellular metabo-
lism, cell cycle progression, apoptosis and autophagy in 
the host cells. MicroRNA expression varies by tissue, 
including within the eye [47, 48]; hence similar changes 
may not occur in other ocular tissues or tissues from 
other immune-privileged sites, such as testis. Future 
studies of the regulatory activities of these miRNAs in 
human RPE cells should delineate their involvement in 
the intraocular persistence of EBOV and EBOV-associ-
ated uveitis in EVD survivors.
Limitations
• We studied EBOV infection in the ARPE-19 human 
RPE cell line, in place of cells isolated from human 
eyes. This cell line is a well-characterized, robust 
model for studying human retinal pigment epithe-
lium [5], and thus our findings should provide rea-
sonable fidelity to an ocular infection in an EVD sur-
vivor.
• MicroRNA expression was evaluated at one time-
point post-infection. The time-point was selected in 
our previously published study [7], to be maximally 
informative of host cell responses to EBOV infection, 
and may be most applicable to EVD and early survi-
vorship.
• Human RPE cells were studied in isolation, while the 
intraocular environment includes multiple cell popu-
lations. However, this approach allowed us to focus 
specifically on gene expression in a key intraocular 
target cell for EBOV.
Table 2 List of  highly-connected protein-coding genes 
(16 most connected) and miRNAs (all connected in EBOV-
infected human RPE cells)
Degree indicates number of interactions for each molecule
Protein-coding genes Degree
LRRK2 181
MAPK13 125
MAPK7 117
PRKCE 66
PRKCH 64
SGK494 64
RND3 52
DIRAS3 44
RASD2 43
RASL11B 43
PDGFRB 37
ARHGEF3 36
IQGAP2 36
ARL14 35
ARL4A 35
miRNA Degree
hsa-miR-190a 58
hsa-miR-29b-3p 25
hsa-miR-130a-5p 17
hsa-miR-32-5p 16
hsa-miR-33a-5p 12
hsa-miR-33b-5p 11
hsa-miR-7-5p 11
hsa-miR-33b-3p 7
hsa-miR-1305 6
hsa-miR-100-3p 5
hsa-miR-19a-5p 5
hsa-miR-101-5p 4
hsa-miR-27b-5p 3
hsa-miR-365a-5p 1
hsa-miR-4521 1
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• Cells were infected with virulent EBOV, which 
caused recent EVD epidemics; less virulent Ebolavi-
rus species may induce different miRNA expression. 
Cells were not co-infected with other pathogens: 
co-infection influences EVD outcome, which might 
in part reflect altered miRNA expression, as demon-
strated in other infections [49, 50].
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